Perampanel May Represent an Effective Treatment for the Prevention of Migraine Comorbid with Epilepsy
Abstract number :
1.301
Submission category :
7. Anti-seizure Medications / 7C. Cohort Studies
Year :
2021
Submission ID :
1826454
Source :
www.aesnet.org
Presentation date :
12/4/2021 12:00:00 PM
Published date :
Nov 22, 2021, 06:54 AM
Authors :
Claudio Liguori, MD, PhD - University "Tor Vergata" of Rome; Mariana Fernandes, PhD - Department of Systems Medicine - University "Tor Vergata" of Rome; Filippo Dainese, MD - Neurologic Unit - SS.Giovanni e Paolo Hospital; Rosaria Renna, MD, PhD - Neurological Clinic and Stroke Unit - “A. Cardarelli” Hospital, Naples, Italy; Mauro Pagliuca, MD - UOC Neurology - “A. Cardarelli” Hospital, Naples, Italy; Francesca Izzi, MD, PhD - Neurology Unit - University Hospital of Rome "Tor Vergata"; Fabio Placidi, MD, PhD - Neurology Unit - University Hospital of Rome "Tor Vergata"; Nicola Mercuri, MD - Neurology Unit - University Hospital of Rome "Tor Vergata"
Rationale: Migraine is a common comorbidity in patients with epilepsy. Considering the proven associations and the common pathophysiological features linking epilepsy and migraine, some antiseizure medications (ASMs) have been considered as a treatment for both disorders. This study aimed at assessing both the effectiveness of PER on epileptic seizures and migraine attacks in patients with epilepsy and comorbid migraine, as well as the reduction of the monthly mean rate usage of rescue migraine medications.
Methods: This observational, multi-centre study included adult patients with epilepsy and comorbid migraine who started PER to better control epileptic seizures and who were followed for 12 months. The study was approved by the Local Ethics Committee of “Tor Vergata” Hospital, and all patients signed an informed consent.
Results: Twenty patients were included (mean age 42.60 ± 13.18 years; 75.0% female). At the 12-month follow-up visit, 15 patients were continuing PER concomitantly with 1 (47.6%) or 2 ASMs (52.3%). A significant reduction of epileptic seizures, migraine attacks and the monthly use of rescue migraine medications between baseline and both 6- and 12-month follow-up visits was documented.
Conclusions: PER demonstrated good effectiveness in reducing both epileptic seizures and migraine attacks in patients with comorbid epilepsy and migraine. Future studies with possibly larger samples are needed to evaluate the efficacy of PER in migraine other than epilepsy.
Funding: Please list any funding that was received in support of this abstract.: None.
Anti-seizure Medications